Participants of Neonatal Brain Injury Breakout

HEIKE RABE, MODERATOR
RONIT PRESSLER, MODERATOR

- GERALDINE BOYLAN
- SERENA COUSELL
- MARIANA CATAPANO
- DAVID EDWARDS
- NICK HALL
- GIOVANNI LESA
- BARRY MANGUM
- NEIL MARLOW
- VANIA OLIVEIRA
- MEHALI PATEL
- RON PORTMAN
- AGNES SAINT-RAYMOND
- PRAKASH SATODIA
- GERT VAN STEENBRUGGE
- LYNN HUDSON, C-Path

By WebEx
- ALBERT ALLEN
- ROBIN HUFF
- KAREN LUYT
- STANLEY ZENGEYA
- QING ZHAO
PRIORITY AREA NEONATAL SEIZURES

- CRITERIA
  - High incidence
  - Burden of disease
  - Clinical relevance
  - Burden to parents
  - Validated biomarkers for short and long term outcome
  - Scientific needs
Neonatal seizures

- Most common neurological emergency in neonatal period
- Incidence in term babies: 2-3/1000 live births, more frequent in preterm
- Most common cause: HIE at term, IVH & PVL in preterm
- Associated with poor neurodevelopmental outcome and epilepsy later in life. Evidence that seizures increase hypoxic brain damage in HIE.
- 1st line treatment not changed over last 50 years, despite fact that phenobarbitone effective in only 50% of babies
- Urgent need to develop new anti-seizure drugs for babies
Response to Breakout Question #2

- For indication X, what non-clinical studies?
  - Neonatal seizures
    - Some models exist, need to be used (in past inadequate models were used)
    - Juvenile animal studies needed for
      - new drugs for toxicity;
      - for prevention of seizures
      - long term effect for all AED
    - Dose finding and PK studies needed: new AED, eg brivaracetam
Neonatal seizures

- Diagnosis is made clinically or aEEG, not adequate for drug development (Boylan et al 2013)
- No evidence base for current management of neonatal seizures (Boots and Evans, 2004; WHO, 2011)
- No new AED developed (1st line PB)
- Risk due to frequent off-label use of antiepileptic drugs (Pressler, et al 2015)
- Outcomes poor (Uria-Avellanal et al 2013)
NEMO: Treatment of NEonatal seizures with Medication Off-patent

- European funded program (FP7)
- 14 partners in 8 countries:
  University College London, University College Cork, Uppsala University Hospital, University Medical Centre Utrecht, Karolinska University Hospital, University of Leeds, Erasmus Universitair MC Rotterdam, Great Ormond Street Hospital.
Acknowledgements

• Colin Binnie
• Stewart Boyd
• Friederike Moeller
• Matthias Ensslen
• Ronit Pressler, Helen Cross, Neil Marlow, Janet Rennie
• Geraldine Boylan, Deidre Murray, B Murphy
• Linda De Vries, Mona Toet, Kees v Huffelen
• Mats Blennow, Boubou Hallberg
• Catherine Chiron, Perrine Plouin, Stephane Auvin
• Gerard Pons, Vincent Jullian
• Sampsa Vanhatalo, M Metsaranta
• Lena Hellstrom-Westas, Johan
• Malcolm Levene, Sharon England
• Renate Swarte
• Yehezkel Ben-Ari,
• Barry Mangum
• Vanshree Patel
• Vincent Grek
• Eli Mizrahi, Paul Coldiz
Evolution of seizures
Extrapolated form adults to neonates limited,
no RCT for most drugs, 1 for phenobarbitone
Master protocol very helpful and achievable in this setting
Drug classes alter inclusion/exclusion criteria only in exceptions
Parameters for modelling & simulation tool depend on drug
PROPOSED STARTER PROJECT NEONATAL BRAIN

- Develop and Write MASTER STUDY PROTOCOL for seizures in Neonatal Neuro-Critical Care
- Start with Term infants and seizures
- Biomarker: continuous EEG
  - Needs standardisation & validation (from existing standards)
- Short term outcome: reduce seizure burden in cEEG

EEG monitoring

Seizure burden

| Drug 1 |
| Drug 2 |
PROPOSED STARTER PROJECT NEONATAL BRAIN

- Develop and Write MASTER STUDY PROTOCOL for seizures in Neonatal Neuro-Critical Care
- Start with Term infants and seizures
- Biomarker: continuous EEG
  - Needs standardisation and validation (from existing published standards)
- Short term outcome: reduce seizure burden in cEEG
- Long term outcome: MRI imaging, neuro-developmental assessments
SHORT ACHIEVABLE GOALS

- MASTER STUDY PROTOCOL
- BRINGS INC TOGETHER ON ACHIEVABLE GOAL
- PUBLISH CONSENSUS STATEMENT IN PEER REVIEWED JOURNAL

- All of the above: measurable deliverables
- Time frame: 1 year
NEXT SLIDES FOR LONG PANEL SESSION
Response to Breakout Question #1

- For neonatal brain injury, what indication(s) are in most need of effective therapies?

- Neonatal seizures
  - Most common neurological emergency in neonatal period: at least 2-3/1000 term births, more common in VLBW
  - Common causes: HIE, IVH / PVL
  - Associated with poor neurodevelopmental outcome & epilepsy

- IVH in preterm
  - Incidence 1-12% in VLBW
  - Associated with poor neurodevelopmental outcome

- White (and gray) matter injury in preterm
  - Incidence 3-4% VLBW
  - Associated with poor neurodevelopmental outcome
Response to Breakout Question #2

- For indication X, what non-clinical studies?
  - Neonatal seizures
    - Some models exist, need to be used (in past inadequate models were used)
    - Juvenile animal studies needed for
      - new drugs for toxicity;
      - for prevention of seizures
      - long term effect for all AED
    - Dose finding and PK studies needed: new AED, eg brivaracetam
  - IVH
    - Some models exist, need to be used
    - Juvenile animal studies should assess drug efficacy for underlying pathophysiology
  - PVL
    - Some models exist, need to be used
    - Juvenile animal studies can mimic chorioamnionitis
Non-clinical studies for neonatal seizures

Phenobarbitone for prevention of seizures
- No juvenile animal toxicity studies needed
- Dose finding and PK studies available for neonates
- RCT to proof efficacy needed

Midazolam
- Juvenile animal toxicity studies needed
- Dose finding and PK studies available for neonates
- RCT to proof efficacy needed

Lidocaine
- No juvenile animal toxicity studies needed
- Dose finding and PK studies available for neonates
- RCT to proof efficacy needed
Non-clinical studies for neonatal seizures

- Levetiracetam
  - Juvenile animal toxicity studies needed
  - Dose finding and PK studies available for neonates
  - RCT on going

- Brivaracetam
  - Juvenile animal toxicity studies needed
  - No dose finding and PK studies
  - RCT to prove efficacy needed

- Topiramate
  - Juvenile animal toxicity studies needed
  - Limited PK and dose finding studies available
  - Non-clinical data be extrapolated to inform some but not all clinical development (concern: specific language impairment)
Response to Breakout Question #3

- What information needed before starting clinical trial?
  - Neonatal seizures
    - Neonatal models need to be tested form beginning as extrapolated form adults to neonates very limited.
    - Master protocol very helpful and achievable in this setting
    - Inclusion/exclusion criteria need to be adapted to drug classes
    - Parameters for modelling & simulation tool depend on drug
  - IVH
    - Establish pathophysiological pathways to be studied in animal modes
    - Investigate protective effects of placental transfusion
  - PVL
    - Animal models to establish pathophysiological pathways
Response to Breakout Question #4

- Are there impediments to establishing a master protocol (do multiple approaches exist – comparative effectiveness studies)? Is there equipoise?
  - Neonatal seizures
    - Master protocol urgently needed to aid new drugs licenced
    - Need for input from industry, academia and regulators
  - IVH
    - Defined inclusion criteria & outcomes needed to aid new drugs licenced
    - Need for input from industry, academia and regulators
  - PVL
    - As above
What potential biomarkers and clinical trial endpoints could be used?

Are any prognostic, predictive, pharmacodynamic, and safety biomarkers available? Are any regulatory ready?

Neonatal seizures
- Validated biomarker: continuous EEG (seizure burden) = primary outcome measure
- Sec outcome measures: rescue drugs, short and long-term neurological (MRI score) outcome

IVH
- Primary outcome measure: prevention IVH (biomarker US / MRI)
- Secondary outcome measure: severity / hydrocephalus

PVL
- Primary outcome measure: prevention PVL (biomarker US / MRI)
- Secondary outcome: progression
Response to Breakout Question #6

- What long-term outcome measures are available to assess the safety and efficacy of the therapy?

  - Neonatal seizures
    - Short term efficacy of seizure burden (contin. EEG)
    - Short term outcome incl MRI score & neuro status
    - Validate neurostatus
    - Long term outcome ages/stages questionnaire or similar
    - Long term outcome at 24 months (Bayley Scales III).
    - Socioeconomic effect & impact on careers of intervention needed

  - IVH
    - Short term outcome incl Sono/MRI score & neuro status
    - Long term outcome ages/stages questionnaire or similar
    - Long term outcome at 24 months (Bayley Scales III).
    - Socioeconomic effect & impact on careers of intervention needed

  - PVL
    - As above
In light of your responses to Questions 1-6, where are the gaps in knowledge and how would you prioritize the studies needed to approach the neonatal brain injury indication?

Neonatal seizures:
- No RCT available for most drugs, need for new anti-seizure drugs
- Master protocol incl meaningful outcome measures needed to aid development and efficacy testing of anti-seizure drugs

IVH
- Indomethacin for prevention
- Definition of common inclusion criteria and outcome measures

PVL
- Animal models for pathophysiology
- Definition of common inclusion criteria and outcome measures
Diagnosis clinically or aEEG - not adequate for drug development (Boylan et al 2013)

No evidence base for current management of neonatal seizures (Boots and Evans, 2004; WHO, 2011)

No new Anti-Epileptic Drug developed for neonatal seizures

Risk due to frequent off-label use of antiepileptic drugs (Silverstein et al 2008; Pressler et al 2015)